Ras

Cat. No.

A63540

CAS No.

2375482-49-6

(R)-BI-2852

(R)-BI-2852 is the isomer of BI-2852, designed as an experimental control in KRAS research. It functions as a KRAS inhibitor targeting the switch I/II pocket with nanomolar affinity, displaying a ten-fold stronger binding to active KRASG12D compared to KRAS wild type. This compound effectively disrupts guanine nucleotide exchange factor, GTPase-activating protein, and effector interactions with KRAS, resulting in the inhibition of downstream signaling pathways and an antiproliferative effect in KRAS mutant cell lines.

Cat. No.

A63541

CAS No.

380470-06-4

Rac1-IN-3

Rac1-IN-3 is an inhibitor of the Rac1 protein, exhibiting an IC50 of 46.1 μM. This compound effectively disrupts Rac1 signaling pathways, which are implicated in various cellular functions such as cytoskeletal dynamics and cell migration. Rac1-IN-3 is valuable for research applications focused on cancer biology, neurodegenerative diseases, and cardiovascular disorders, providing insights into the role of Rac1 in disease progression and therapeutic targeting.

Cat. No.

A63542

CAS No.

2937327-83-6

pan-KRAS-IN-18

pan-KRAS-IN-18 is a pan-KRAS inhibitor targeting both KRAS wild-type and KRAS G12V, with IC50 values of 29 nM and 9 nM, respectively. This compound demonstrates significant antiproliferative activity in KRAS-mutant cell lines, making it a valuable tool for researchers studying KRAS-driven cancers. Its application is particularly relevant in the context of lung cancer research.

Cat. No.

A63543

CAS No.

2762240-36-6

Divarasib adipate

Synonyms: GDC-6036 adipate

Divarasib adipate is a potent and selective inhibitor of KRAS G12C with an IC50 of

Cat. No.

A63544

CAS No.

2988148-70-3

MRTX-EX185 formic

MRTX-EX185 formic is a potent inhibitor of KRAS(G12D) with an IC50 of 90 nM. It effectively binds to both GDP-loaded and active GTP-bound states of KRAS, displaying broad-spectrum activity with additional IC50 values of 110, 290, 130, and 240 nM for KRAS WT, KRAS(G12C), KRAS(Q61H), and KRAS(G13D), respectively. MRTX-EX185 formic also shows affinity for GDP-loaded HRAS. This compound is valuable for investigating RAS-driven tumors, including pancreatic cancer, facilitating insights into therapeutic strategies targeting KRAS mutations.

Cat. No.

A63545

CAS No.

3034588-80-9

Pan-RAS-IN-3

Pan-RAS-IN-3 is a pan-RAS inhibitor that targets various isoforms of the RAS protein family, known for their role in promoting cellular proliferation and survival. This compound exhibits significant biological activity in inhibiting the signaling pathways associated with melanoma and acute myeloid leukemia. It is a valuable tool for researchers investigating RAS-driven cancers and studying the therapeutic potential of targeting these oncogenic signaling pathways.

Cat. No.

A63546

CAS No.

3030576-47-4

KRAS inhibitor-24

KRAS inhibitor-24 is a pyridopyrimidine compound that selectively inhibits KRAS with an IC50 of less than 100 nM for KRas G12V, KRas WT, and KRas G12R mutants. This compound demonstrates substantial biological activity in disrupting KRAS-mediated signaling pathways. KRAS inhibitor-24 is utilized in preclinical research to study KRAS-driven tumors and to investigate potential therapeutic strategies targeting KRAS mutations in various cancers.

Cat. No.

A63547

CAS No.

3030576-46-3

(1R)-KRAS inhibitor-24

(1R)-KRAS inhibitor-24 is a pyridopyrimidine compound that selectively inhibits KRAS, demonstrating an IC50 of less than 100 nM for KRas G12V, KRas Wild Type, and KRas G12R variants. This inhibitor serves as a valuable tool for research applications focused on KRAS-driven cancers, providing insights into signaling pathways and potential therapeutic modalities targeting this critical oncogene.

Cat. No.

A63548

CAS No.

3024060-23-6

KRAS G12D-IN-31

KRAS G12D-IN-31 is a potent inhibitor of the KRAS G12D mutation, exhibiting an IC50 of less than 100 nM. It effectively inhibits the proliferation of RAS-dependent cancer cells, including those harboring KRAS G12C, KRAS G12D, KRAS G12V, and KRASWT. This compound is particularly valuable for research applications involving non-small cell lung cancer, gastric cancer, colon cancer, and malignant melanoma, facilitating the exploration of KRAS-targeted therapies.

Cat. No.

A63550

CAS No.

2847881-81-4

TH-Z827

TH-Z827 is a selective inhibitor of the KRAS(G12D) mutant, demonstrating an IC50 of 2.4 μM. This compound does not interact with wild-type KRAS or the KRAS(G12C) variant. TH-Z827 effectively disrupts the interaction between KRAS(G12D) and CRAF, with an IC50 value of 42 μM, making it a valuable tool for studying KRAS-driven cancers and developing targeted therapies.

Cat. No.

A63551

CAS No.

2757095-12-6

KRAS G12D inhibitor 3 TFA

KRAS G12D Inhibitor 3 TFA is a selective inhibitor targeting the KRAS G12D mutation, exhibiting an IC50 of less than 500 nM. This compound demonstrates significant antitumor activity, making it a valuable tool in cancer research related to KRAS-driven malignancies. Additionally, KRAS G12D Inhibitor 3 TFA features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), thus facilitating the development of bioconjugates and other applications in chemical biology.

Cat. No.

A63552

CAS No.

591726-26-0

(E/Z)-ZINC09659342

(E/Z)-ZINC09659342 is a potent inhibitor of the Lbc-RhoA protein interaction, impacting RhoA-mediated cellular signaling pathways. This compound is valuable for studies focused on RhoA's role in cell adhesion, migration, and cytoskeletal dynamics. It serves as a useful tool for researchers investigating the molecular mechanisms of various diseases associated with RhoA dysregulation.

Cat. No.

A63555

CAS No.

2349393-95-7

KRAS G12C inhibitor 14

KRAS G12C inhibitor 14 is a potent inhibitor specifically targeting the KRAS G12C mutation, with an IC50 value of 18 nM. This compound effectively disrupts the activity of the KRAS protein, making it a valuable tool for studies on cancer biology, particularly in models of tumors driven by KRAS mutations. Its application extends to drug discovery and development efforts aimed at novel therapeutic strategies for KRAS-driven malignancies.

Cat. No.

A63556

CAS No.

1945941-72-9

ADT-1004

ADT-1004 is an orally active prodrug of the pan-RAS inhibitor ADT-007, which is characterized by its reversible, high potency and selectivity. By binding to the nucleotide-free conformation of RAS proteins, ADT-007 effectively inhibits GTP activation, subsequently blocking downstream MAPK and AKT signaling pathways. ADT-1004 is primarily utilized in research focused on pancreatic ductal adenocarcinoma, providing a valuable tool for the investigation of RAS-mediated oncogenic processes.

Cat. No.

A63559

CAS No.

1922098-90-5

MRTF/SRF-IN-1

MRTF/SRF-IN-1 is a selective inhibitor of myocardin-related transcription factor and serum response factor (MRTF/SRF). This compound is utilized in research aimed at understanding the role of MRTF/SRF in cancer progression and fibrotic diseases. It has potential applications in studying molecular pathways associated with cellular proliferation and fibrosis.

Cat. No.

A63561

CAS No.

2648221-05-8

KRAS G12D inhibitor 8

KRAS G12D inhibitor 8 is a selective inhibitor of the KRAS G12D oncogene, a key member of the Ras protein family involved in critical intracellular signaling pathways that regulate cell growth and development. This compound exhibits potent anti-cancer activity, making it a valuable tool for research focused on KRAS G12D-driven malignancies. Its application in preclinical studies may provide insights into therapeutic strategies targeting KRAS mutations associated with various cancers.

Cat. No.

A63563

CAS No.

195981-08-9

BMS-214662 hydrochloride

BMS-214662 hydrochloride is a potent farnesyltransferase inhibitor that disrupts the prenylation of Ras proteins, preventing their localization and function at the cell membrane. This inhibition leads to significant anti-tumor activity, making it a valuable tool for cancer research. The compound demonstrates a high affinity for H-Ras with an IC50 of 1.3 nM and for K-Ras with an IC50 of 8.4 nM, highlighting its potential in studying tumorigenesis associated with Ras signaling pathways.

Cat. No.

A63565

CAS No.

2621928-53-6

KRAS G12D inhibitor 5

KRAS G12D inhibitor 5 is a selective inhibitor targeting the mutated KRAS G12D protein, a key driver in various malignancies, including pancreatic cancer. This compound is valuable in research applications focusing on the therapeutic mechanisms underlying KRAS-driven tumorigenesis and may help elucidate the pathways involved in cancer progression and resistance.

Cat. No.

A63566

CAS No.

2839563-01-6

Sosimerasib

Sosimerasib is an orally active inhibitor targeting KRAS G12C mutations. It exhibits significant functional inhibitory effects on mutant KRAS G12C proteins, making it a valuable tool for studying signaling pathways involved in cancer progression. This compound is particularly relevant for research applications focused on non-small cell lung cancer.

Cat. No.

A63567

CAS No.

2621927-57-7

MRTX-EX185

MRTX-EX185 is a selective inhibitor of KRAS(G12D) with an IC50 of 90 nM, effectively binding to both GDP-loaded and active GTP-bound states of KRAS. This compound demonstrates broad-spectrum activity against various KRAS mutations, including KRAS WT, KRAS (G12C), KRAS (Q61H), and KRAS (G13D), with IC50 values ranging from 110 nM to 290 nM. Additionally, MRTX-EX185 interacts with GDP-loaded HRAS. This reagent is valuable for investigating RAS-driven tumors, particularly in the context of pancreatic cancer research.

Cat. No.

A63568

CAS No.

2946593-60-6

(R)-G12Di-7

(R)-G12Di-7 is a covalent inhibitor specifically targeting K-Ras-G12D. This compound selectively binds to the K-Ras-G12D·GDP and K-Ras-G12D·GppNHp complexes, effectively labeling them. (R)-G12Di-7 demonstrates significant inhibitory activity against cancer cells harboring the G12D mutation, making it a valuable tool for research into K-Ras-related oncogenic signaling and potential therapeutic interventions.

Cat. No.

A63569

CAS No.

2706637-12-7

(7R)-Elisrasib

Synonyms: (7R)-D3S-001

(7R)-Elisrasib is a selective inhibitor targeting the KRASG12C mutation, a key driver in various cancers. This compound demonstrates potent antitumor activity, effectively inhibiting tumor growth in preclinical mouse models. It is primarily used in cancer research focused on KRAS-driven tumors and aids in the investigation of targeted therapies for oncogenic mutations.

Cat. No.

A63570

CAS No.

2649004-88-4

KRAS G12C inhibitor 28

KRAS G12C inhibitor 28 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting an IC50 of 57 nM. This compound demonstrates significant antitumor activity and is utilized in research focusing on KRAS-driven cancers. Its applications include investigating the therapeutic potential of KRAS inhibition in various oncological studies.

Cat. No.

A63571

CAS No.

2252242-32-1

RAS GTPase inhibitor 1

RAS GTPase inhibitor 1 is a specific inhibitor targeting RAS GTPase, known for its significant anti-tumor activity. This compound demonstrates an effective EC50 of less than 1 μM in facilitating nucleotide exchange and an IC50 of less than 1 μM in H727 cancer cells. It is valuable for research applications aimed at understanding RAS signaling pathways and developing targeted cancer therapies.

Cat. No.

A63572

CAS No.

2376328-55-9

K-Ras G12C-IN-4

K-Ras G12C-IN-4 is a potent covalent inhibitor targeting the KRAS G12C mutation. This compound effectively disrupts the oncogenic signaling pathways associated with mutant KRAS, making it a valuable tool in cancer research. Its application extends to studying therapeutic approaches for tumors harboring KRAS G12C mutations, providing insights into potential treatment strategies.